Abstract
Patients with mastocytosis have symptoms related to the tissue response to the release of mediators from mast cells (MC), local mast cell burden or associated non-mast cell hematological disorders. MC contain an array of biologically active mediators in their granules, which are preformed and stored. MC are also able to produce newly generated membrane-derived lipid mediators and are a source of multifunctional cytokines. Mediator-related symptoms can include pruritus, flushing, syncope, gastric distress, nausea and vomiting, diarrhea, bone pain and neuropsychiatric disturbances; these symptoms are variably controlled by adequate medications. Management of patients within all categories of mastocytosis includes: a) a careful counseling of patients (parents in pediatric cases) and care providers, b) avoidance of factors triggering acute mediator release, c) treatment of acute and chronic MC-mediator symptoms and, if indicated, d) an attempt for cytoreduction and treatment of organ infiltration by mast cells.
Keywords: Mastocytosis, mast cell-mediator related symptoms, treatment
Inflammation & Allergy - Drug Targets (Discontinued)
Title: Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Volume: 5 Issue: 1
Author(s): Luis Escribano, Cem Akin, Mariana Castells and Lawrence B. Schwartz
Affiliation:
Keywords: Mastocytosis, mast cell-mediator related symptoms, treatment
Abstract: Patients with mastocytosis have symptoms related to the tissue response to the release of mediators from mast cells (MC), local mast cell burden or associated non-mast cell hematological disorders. MC contain an array of biologically active mediators in their granules, which are preformed and stored. MC are also able to produce newly generated membrane-derived lipid mediators and are a source of multifunctional cytokines. Mediator-related symptoms can include pruritus, flushing, syncope, gastric distress, nausea and vomiting, diarrhea, bone pain and neuropsychiatric disturbances; these symptoms are variably controlled by adequate medications. Management of patients within all categories of mastocytosis includes: a) a careful counseling of patients (parents in pediatric cases) and care providers, b) avoidance of factors triggering acute mediator release, c) treatment of acute and chronic MC-mediator symptoms and, if indicated, d) an attempt for cytoreduction and treatment of organ infiltration by mast cells.
Export Options
About this article
Cite this article as:
Escribano Luis, Akin Cem, Castells Mariana and Schwartz B. Lawrence, Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis, Inflammation & Allergy - Drug Targets (Discontinued) 2006; 5 (1) . https://dx.doi.org/10.2174/187152806775269303
DOI https://dx.doi.org/10.2174/187152806775269303 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Beneficial Role of Vitexin and Isovitexin Flavonoids in the Vascular Endothelium and Cardiovascular System
Current Nutraceuticals Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Evaluation of Clinical Efficacy of Fasudil for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design An Overview of Phytochemical and Pharmacological Profile of <i>Morus alba</i> Linn
Current Bioactive Compounds Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Causal Mechanisms Underlying Periventricular Leukomalacia and Cerebral Palsy
Current Pediatric Reviews Therapeutical Relevance of MAP-Kinase Inhibitors in Renal Diseases: Current Knowledge and Future Clinical Perspectives
Current Medicinal Chemistry Single-dose Pharmacokinetics and Tolerability of Oral Delta-9- Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis
Drug Metabolism Letters Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents
Infectious Disorders - Drug Targets New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Perioperative Management of Hyperlipidemia Medications
Current Clinical Pharmacology Effects of Onion Extract on Endogenous Vascular H2S and Adrenomedulin in Rat Atherosclerosis
Current Pharmaceutical Biotechnology Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Renal Complications of Fabry Disease
Current Pharmaceutical Design Pathogenesis and Management of Intradialytic Hypertension
Current Hypertension Reviews Targeting Nanoparticles as Drug Delivery Systems for Cancer Treatment
Current Nanoscience